Rema Menon
Payments from drug & device makers
Across 200 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$632
- AstraZeneca$534
- Lilly USA, LLC$361
- AbbVie$311
- Novo Nordisk$294
- Boehringer Ingelheim$233
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,661100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$3,661 in reported general payments places this provider in the 80th percentile of 755 medical providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 44 | $51,650 |
| OzempicSemaglutide | 28 | $45,413 |
| JardianceEmpagliflozin | 25 | $34,245 |
| FarxigaDapagliflozin Propanediol | 29 | $33,499 |
| MounjaroTirzepatide | 18 | $28,931 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $25,731 |
| JanuviaSitagliptin Phosphate | 14 | $20,492 |
| TrulicityDulaglutide | 13 | $17,078 |
| XareltoRivaroxaban | 11 | $14,329 |
| Atorvastatin Calcium | 255 | $3,360 |
| Metoprolol Succinate | 141 | $2,495 |
| Losartan Potassium | 156 | $2,200 |
| Rosuvastatin Calcium | 109 | $1,514 |
| Amlodipine Besylate | 158 | $1,077 |
| Ezetimibe | 36 | $996 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $632 | $51,65044 claims |
| Lilly USA, LLCMounjaro, Trulicity | $361 | $46,01031 claims |
| Novo NordiskOzempic | $294 | $45,41328 claims |
| Boehringer IngelheimJardiance | $233 | $34,24525 claims |
| AstraZenecaFarxiga | $534 | $33,49929 claims |
| GSKTrelegy Ellipta | $153 | $25,73128 claims |
| MerckJanuvia | $125 | $20,49214 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $24 | $76179 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 755 medical providers in Michigan.
Other medical in Novi
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$66K
- David WilkinsMuskegon$41K
- Mark RosenBerkley$32K
- Robert DemeesterRoyal Oak$27K
- John BrabantDetroit$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.